SGEN:NSD-Seattle Genetics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 151.73

Change

-4.04 (-2.59)%

Market Cap

USD 26.26B

Volume

3.42M

Average Target Price

USD 135.97 (-10.39%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and biotechnology and pharmaceutical companies. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-18.46 (-6.48%)

USD73.88B 49.39 37.03
REGN Regeneron Pharmaceuticals, Inc

-24.70 (-4.33%)

USD64.13B 28.64 21.76
ALXN Alexion Pharmaceuticals, Inc

+1.30 (+1.28%)

USD22.70B 9.81 8.43
INCY Incyte Corporation

-0.69 (-0.69%)

USD21.60B 47.64 35.20
MRNA Moderna, Inc

-11.29 (-16.36%)

USD21.42B N/A N/A
GMAB Genmab A/S

+1.22 (+4.16%)

USD19.59B 52.40 5.57
BMRN BioMarin Pharmaceutical Inc

+6.23 (+6.39%)

USD17.63B 154.78 92.86
ALNY Alnylam Pharmaceuticals, Inc

-4.09 (-2.91%)

USD16.13B N/A N/A
GLPG Galapagos NV

+4.45 (+2.22%)

USD13.13B 70.13 37.04
BGNE BeiGene, Ltd

+4.78 (+3.00%)

USD12.41B N/A N/A

ETFs Containing SGEN

Symbol Name Weight Mer Price(Change) Market Cap
IDNA iShares Genomics Immunolo.. 5.11 % 0.47 %

-1.24 (-3.35%)

USD0.06B
FBT First Trust NYSE Arca Bio.. 3.88 % 0.55 %

-2.08 (-1.26%)

USD1.81B
ENTR ERShares Entrepreneur 30 .. 3.87 % 0.49 %

-0.03 (-0.17%)

USD0.11B
BTEC Principal Healthcare Inno.. 3.44 % 0.42 %

-0.94 (-2.17%)

USD0.07B
IBB iShares Nasdaq Biotechnol.. 3.25 % 0.47 %

-2.53 (-1.90%)

USD7.94B
BBP Virtus LifeSci Biotech Pr.. 3.09 % 0.79 %

-0.41 (-0.87%)

USD0.02B
PTH Invesco DWA Healthcare Mo.. 2.96 % 0.60 %

-2.67 (-2.31%)

USD0.27B
FXH First Trust Health Care A.. 2.85 % 0.62 %

-0.70 (-0.78%)

USD1.71B
BTEK:LSE iShares Nasdaq US Biotech.. 2.69 % 0.35 %

-0.05 (-0.92%)

USD0.10B
BTEE:LSE iShares Nasdaq US Biotech.. 2.69 % 0.35 %

+0.03 (+0.51%)

USD0.10B
FHH:CA FT AlphaDEX U.S. Health C.. 2.58 % 0.70 %

-0.11 (-0.32%)

USD0.01B
BTEC:LSE iShares Nasdaq US Biotech.. 2.51 % 0.35 %

+0.02 (+0.40%)

USD0.07B
XBI SPDR S&P Biotech ETF 2.45 % 0.35 %

-2.50 (-2.36%)

USD3.76B
ZBIO ProShares UltraPro Short .. 2.25 % 0.95 %

N/A

USD2.51M
BIS ProShares UltraShort Nasd.. 2.25 % 0.95 %

+0.33 (+3.82%)

USD0.01B
ZUH:CA BMO Equal Weight US Healt.. 1.98 % 0.35 %

-0.54 (-0.88%)

USD0.35B
QQXT First Trust NASDAQ-100 Ex.. 1.97 % 0.60 %

+0.55 (+0.94%)

USD0.10B
ZHU:CA BMO Equal Weight US Healt.. 1.88 % 0.35 %

-0.42 (-1.12%)

USD0.01B
EDGE:CA Evolve Innovation Index F.. 1.70 % 0.48 %

N/A

USD0.01B
ITEK:LSE HAN-GINS Innovative Techn.. 1.64 % 0.75 %

+0.23 (+2.44%)

USD5.53M
2B78:XETRA iShares Healthcare Innova.. 1.54 % 0.40 %

-0.12 (-1.72%)

USD0.71B
HEAL:LSE iShares Healthcare Innova.. 1.43 % 0.40 %

+0.11 (+1.50%)

USD0.51B
DRDR:LSE iShares Healthcare Innova.. 1.43 % 0.40 %

+1.13 (+0.19%)

USD0.47B
QQQE Direxion NASDAQ-100 Equal.. 1.19 % 0.35 %

+0.45 (+0.82%)

USD0.22B
QQEW First Trust NASDAQ-100 Eq.. 1.18 % 0.59 %

+0.64 (+0.87%)

USD0.73B
FTC First Trust Large Cap Gro.. 1.10 % 0.61 %

-0.05 (-0.07%)

USD0.83B
XT iShares Exponential Techn.. 0.77 % 0.47 %

+0.60 (+1.44%)

USD2.18B
2B77:XETRA iShares Ageing Population.. 0.67 % 0.40 %

+0.02 (+0.31%)

USD0.24B
AGES:LSE iShares Ageing Population.. 0.67 % 0.40 %

+9.20 (+2.11%)

USD0.24B
FEX:LSE First Trust US Large Cap .. 0.61 % 0.75 %

+82.50 (+2.31%)

USD0.11B
FEXD:LSE First Trust US Large Cap .. 0.61 % 0.75 %

+78.00 (+2.32%)

USD0.11B
FAD First Trust Multi Cap Gro.. 0.55 % 0.66 %

+0.26 (+0.35%)

USD0.14B
FEX First Trust Large Cap Cor.. 0.55 % 0.60 %

+1.37 (+2.44%)

USD0.90B
AGED:LSE iShares Ageing Population.. 0.54 % 0.40 %

+0.18 (+3.44%)

USD0.28B
TUSA First Trust Total US Mark.. 0.52 % 0.70 %

+0.86 (+2.95%)

USD0.01B
ETHO Etho Climate Leadership U.. 0.47 % 0.47 %

+0.95 (+2.47%)

USD0.07B
BLES Inspire Global Hope ETF 0.44 % 0.52 %

+0.92 (+3.79%)

USD0.11B
EUSA iShares MSCI USA Equal We.. 0.27 % 0.15 %

+1.33 (+2.46%)

USD0.18B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-2.83 (-4.07%)

USD0.15B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.12 (-2.12%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.79% 72% C- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.79% 72% C- 88% B+
Trailing 12 Months  
Capital Gain 119.45% 86% B 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 119.45% 86% B 94% A
Trailing 5 Years  
Capital Gain 257.01% 92% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 257.01% 92% A- 93% A
Average Annual (5 Year Horizon)  
Capital Gain 30.18% 77% C+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.18% 77% C+ 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 38.52% 63% D 36% F
Risk Adjusted Return 78.36% 95% A 76% C
Market Capitalization 26.26B 100% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 15.12 12% F 7% F
Price / Cash Flow Ratio -160.41 99% A+ 97% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -20.38% 87% B+ 34% F
Return on Invested Capital -14.00% 85% B 29% F
Return on Assets -9.48% 87% B+ 28% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.48 47% F 30% F
Short Percent 8.32% 35% F 26% F
Beta 1.40 56% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.